Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.
-
Alumis reports third quarter 2025 financial results and highlights recent progress and anticipated milestones including Phase 3 data in early 1Q 2026
-
Alumis to participate in two upcoming November investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conf and the Stifel 2025 Healthcare Conf
-
EXTON, PA, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance...
-
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
-
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026
-
Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases
-
Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.
-
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and...
-
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.